Analysis of Liquidity Ratios
Liquidity ratios measure the company ability to meet its short-term obligations.
Liquidity Ratios (Summary)
IQVIA Holdings Inc., liquidity ratios
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Current ratio | 0.89 | 0.91 | 1.12 | 1.05 | 1.10 | |
| Quick ratio | 0.76 | 0.77 | 0.95 | 0.88 | 0.94 | |
| Cash ratio | 0.23 | 0.28 | 0.42 | 0.23 | 0.27 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | IQVIA Holdings Inc. current ratio deteriorated from 2020 to 2021 and from 2021 to 2022. |
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | IQVIA Holdings Inc. quick ratio deteriorated from 2020 to 2021 and from 2021 to 2022. |
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | IQVIA Holdings Inc. cash ratio deteriorated from 2020 to 2021 and from 2021 to 2022. |
Current Ratio
IQVIA Holdings Inc., current ratio calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | 4,981) | 4,763) | 5,090) | 4,126) | 3,874) | |
| Current liabilities | 5,578) | 5,241) | 4,558) | 3,945) | 3,534) | |
| Liquidity Ratio | ||||||
| Current ratio1 | 0.89 | 0.91 | 1.12 | 1.05 | 1.10 | |
| Benchmarks | ||||||
| Current Ratio, Competitors2 | ||||||
| AbbVie Inc. | 0.96 | 0.79 | 0.84 | 3.18 | — | |
| Amgen Inc. | 1.41 | 1.59 | 1.81 | 1.44 | — | |
| Bristol-Myers Squibb Co. | 1.25 | 1.52 | 1.58 | 1.60 | — | |
| Danaher Corp. | 1.89 | 1.43 | 1.86 | 5.19 | — | |
| Eli Lilly & Co. | 1.05 | 1.23 | 1.40 | 1.16 | — | |
| Gilead Sciences Inc. | 1.29 | 1.27 | 1.40 | 3.10 | — | |
| Johnson & Johnson | 0.99 | 1.35 | 1.21 | 1.26 | — | |
| Merck & Co. Inc. | 1.47 | 1.27 | 1.02 | 1.24 | — | |
| Pfizer Inc. | 1.22 | 1.40 | 1.35 | 0.88 | — | |
| Regeneron Pharmaceuticals Inc. | 5.06 | 3.56 | 3.63 | 3.67 | — | |
| Thermo Fisher Scientific Inc. | 1.48 | 1.50 | 2.13 | 1.92 | — | |
| Vertex Pharmaceuticals Inc. | 4.83 | 4.46 | 4.33 | 3.61 | — | |
| Current Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 1.30 | 1.36 | 1.37 | — | — | |
| Current Ratio, Industry | ||||||
| Health Care | 1.15 | 1.21 | 1.20 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Current ratio = Current assets ÷ Current liabilities
= 4,981 ÷ 5,578 = 0.89
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | IQVIA Holdings Inc. current ratio deteriorated from 2020 to 2021 and from 2021 to 2022. |
Quick Ratio
IQVIA Holdings Inc., quick ratio calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and cash equivalents | 1,216) | 1,366) | 1,814) | 837) | 891) | |
| Trade accounts receivable and unbilled services, net | 2,917) | 2,551) | 2,410) | 2,582) | 2,394) | |
| Investments in debt, equity and other securities | 93) | 111) | 88) | 62) | 47) | |
| Total quick assets | 4,226) | 4,028) | 4,312) | 3,481) | 3,332) | |
| Current liabilities | 5,578) | 5,241) | 4,558) | 3,945) | 3,534) | |
| Liquidity Ratio | ||||||
| Quick ratio1 | 0.76 | 0.77 | 0.95 | 0.88 | 0.94 | |
| Benchmarks | ||||||
| Quick Ratio, Competitors2 | ||||||
| AbbVie Inc. | 0.69 | 0.56 | 0.60 | 2.91 | — | |
| Amgen Inc. | 0.95 | 1.06 | 1.30 | 1.01 | — | |
| Bristol-Myers Squibb Co. | 0.87 | 1.20 | 1.28 | 1.26 | — | |
| Danaher Corp. | 1.30 | 0.89 | 1.36 | 4.68 | — | |
| Eli Lilly & Co. | 0.63 | 0.80 | 0.85 | 0.68 | — | |
| Gilead Sciences Inc. | 0.99 | 0.95 | 1.08 | 2.86 | — | |
| Johnson & Johnson | 0.71 | 1.04 | 0.91 | 0.94 | — | |
| Merck & Co. Inc. | 0.93 | 0.73 | 0.58 | 0.78 | — | |
| Pfizer Inc. | 0.80 | 1.00 | 0.78 | 0.50 | — | |
| Regeneron Pharmaceuticals Inc. | 4.16 | 2.98 | 2.86 | 2.81 | — | |
| Thermo Fisher Scientific Inc. | 1.06 | 1.00 | 1.63 | 1.19 | — | |
| Vertex Pharmaceuticals Inc. | 4.46 | 4.04 | 4.02 | 3.33 | — | |
| Quick Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.91 | 0.98 | 0.98 | — | — | |
| Quick Ratio, Industry | ||||||
| Health Care | 0.86 | 0.89 | 0.89 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 4,226 ÷ 5,578 = 0.76
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | IQVIA Holdings Inc. quick ratio deteriorated from 2020 to 2021 and from 2021 to 2022. |
Cash Ratio
IQVIA Holdings Inc., cash ratio calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cash and cash equivalents | 1,216) | 1,366) | 1,814) | 837) | 891) | |
| Investments in debt, equity and other securities | 93) | 111) | 88) | 62) | 47) | |
| Total cash assets | 1,309) | 1,477) | 1,902) | 899) | 938) | |
| Current liabilities | 5,578) | 5,241) | 4,558) | 3,945) | 3,534) | |
| Liquidity Ratio | ||||||
| Cash ratio1 | 0.23 | 0.28 | 0.42 | 0.23 | 0.27 | |
| Benchmarks | ||||||
| Cash Ratio, Competitors2 | ||||||
| AbbVie Inc. | 0.31 | 0.28 | 0.30 | 2.56 | — | |
| Amgen Inc. | 0.59 | 0.66 | 0.91 | 0.69 | — | |
| Bristol-Myers Squibb Co. | 0.42 | 0.78 | 0.83 | 0.84 | — | |
| Danaher Corp. | 0.71 | 0.32 | 0.82 | 4.04 | — | |
| Eli Lilly & Co. | 0.13 | 0.26 | 0.29 | 0.21 | — | |
| Gilead Sciences Inc. | 0.57 | 0.56 | 0.65 | 2.50 | — | |
| Johnson & Johnson | 0.42 | 0.70 | 0.59 | 0.54 | — | |
| Merck & Co. Inc. | 0.54 | 0.34 | 0.30 | 0.47 | — | |
| Pfizer Inc. | 0.54 | 0.73 | 0.47 | 0.26 | — | |
| Regeneron Pharmaceuticals Inc. | 2.46 | 1.45 | 1.33 | 1.53 | — | |
| Thermo Fisher Scientific Inc. | 0.50 | 0.33 | 1.00 | 0.39 | — | |
| Vertex Pharmaceuticals Inc. | 3.93 | 3.51 | 3.55 | 2.85 | — | |
| Cash Ratio, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.52 | 0.58 | 0.59 | — | — | |
| Cash Ratio, Industry | ||||||
| Health Care | 0.47 | 0.50 | 0.51 | — | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 1,309 ÷ 5,578 = 0.23
2 Click competitor name to see calculations.
| Liquidity ratio | Description | The company |
|---|---|---|
| Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | IQVIA Holdings Inc. cash ratio deteriorated from 2020 to 2021 and from 2021 to 2022. |